The Recall Desk
HighFDA (Drugs)·D-0097-2026·Announced 2025-10-29

Opdualag injection vials recalled from one lot over sterility assurance

Bristol-Myers Squibb is recalling 12,778 vials of Opdualag (nivolumab and relatlimab-rmbw) injection from one lot for lack of assurance of sterility.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Scored 3 under the risk-of-harm criterion: a loss of sterility assurance in an injectable creates an infection risk, and no injuries are reported.

Plain-English summary

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL, in single dose vials from Bristol-Myers Squibb of Princeton, New Jersey, is being recalled for lack of assurance of sterility.

The recall covers 12,778 vials from lot 033A23B, expiring 30 April 2026, carrying NDC 0003-7125-11. The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.

Sterility matters for an injectable because the product is administered directly into the body. The enforcement record describes a loss of sterility assurance rather than confirmed contamination, and reports no injuries.

Facilities holding the affected lot should quarantine it and follow the firm's instructions.

The recalled product

Product
OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Brand
OPDUALAG
Affected units
12,778

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot: 033A23B
  • Expiry: 4/30/2026

Distribution

Distributed nationwide across the United States.